Patient outcomes and healthcare utilisation following implementation of an advanced therapy care pathway for inflammatory bowel disease: a multicentre, prospective quasi-experimental preimplementation/postimplementation study in the Netherlands - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating Patient Outcomes and Healthcare Utilization After the Introduction of an Advanced Therapy Care Pathway for Inflammatory Bowel Disease: A Multicenter, Prospective Quasi-Experimental Study in the Netherlands

  • By

  • Elyke H Visser

  • Martijn A Oude Voshaar

  • Reinier C A Van Linschoten

  • Jildou Hoekstra

  • Kristin Robbers

  • Vincent de Jonge

  • Edith Koehler

  • K Evelyne Verweij

  • Sanne van der Wiel

  • Daniëlle van der Horst

  • C Janneke van der Woude

  • Desiree van Noord

  • Rachel L West

  • on behalf of the Southwest Netherlands IBD Study Group

  • October 1, 2026

Share

  • 1

    The study evaluated the impact of an advanced therapy care pathway (ACP) on inflammatory bowel disease (IBD) outcomes and healthcare utilization in the Netherlands.

  • 2

    A total of 1173 patients participated, with Crohn’s disease being the most common diagnosis at 64%.

  • 3

    Emergency room visits and hospital admissions significantly decreased six months after ACP implementation, with only admissions directly attributable to the ACP.

  • 4

    Disease control remained high and unchanged post-implementation, indicating that ACP did not compromise patient outcomes.

  • 5

    The study suggests that structured care pathways can standardize IBD treatment and potentially reduce healthcare costs without affecting patient quality of care.

Original Source(s)

Patient outcomes and healthcare utilisation following implementation of an advanced therapy care pathway for inflammatory bowel disease: a multicentre, prospective quasi-experimental preimplementation/postimplementation study in the Netherlands

  • by Elyke H Visser, Martijn A Oude Voshaar, Reinier C A Van Linschoten, Jildou Hoekstra, Kristin Robbers, Vincent de Jonge, Edith Koehler, K Evelyne Verweij, Sanne van der Wiel, Daniëlle van der Horst, C Janneke van der Woude, Desiree van Noord, Rachel L West, on behalf of the Southwest Netherlands IBD Study Group

  • October 1, 2026

Related Content

Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis

Strategies for Organ Regeneration Using Cell Therapy

The 2026 IBD UK Standards of healthcare service design and delivery for adults and children living with Crohn’s disease and ulcerative colitis